Phase I/II clinical trial - Phases précoces tumeurs solides

Phases précoces tumeurs solides
Essai clinique fermé
Public cible
A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with NUT midline carcinoma(NMC) and other cancers.
Description de l'essai
This trial evaluated an oral bromo-domain inhibitor in patients with midline carcinoma, HER2-negative breast cancer and any tumor type harbouring a N-MYC amplification.